Kovaltry (Octocog Alfa)

Kovaltry is a recombinant factor VIII used to manage disorders of the intrinsic coagulation pathway, primarily hemophilia A.

• Hemophilia A (congenital factor VIII deficiency): provides prophylactic protection against spontaneous and traumatic bleeding.
• Surgical prophylaxis in hemophilia A patients: ensures adequate factor levels to minimise intra‑operative blood loss.
• On‑demand treatment of bleeding episodes in hemophilia A: rapidly restores clotting activity to stop active bleeds.

• Octocog Alfa is a recombinant form of human factor VIII that circulates in plasma bound to von Willebrand factor. When administered intravenously, it replaces the missing endogenous factor VIII, enabling the activation of factor X within the intrinsic coagulation cascade, which leads to thrombin generation and formation of a stable fibrin clot.

Kovaltry may be associated with a range of adverse reactions following intravenous infusion.

Common Side Effects

• Infusion‑related reactions (e.g., chills, flushing)
• Headache
• Fever or chills
• Nausea
• Arthralgia or joint discomfort
• Fatigue or malaise

Serious or Rare Side Effects

• Development of inhibitory antibodies against factor VIII
• Anaphylactic or severe allergic reactions
• Thrombotic events (e.g., deep‑vein thrombosis)
• Severe hemolysis
• Acute renal impairment
• Disseminated intravascular coagulation (rare).

When using Kovaltry, clinicians should observe several safety measures.

• Individualized dosing: adjust based on patient’s factor VIII activity and clinical response.
• Inhibitor monitoring: regularly test for anti‑factor VIII antibodies, especially after repeated exposure.
• Allergy caution: avoid in patients with known hypersensitivity to any component of the product.
• Surgical planning: ensure adequate factor levels are achieved before any invasive procedure.
• Concomitant therapy: assess risk when used with other hemostatic agents.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kovaltry can interact with other agents that affect hemostasis or immune response.

Major Interactions (Avoid)

• Concurrent use of other factor VIII concentrates: may increase risk of inhibitor development.
• Immune tolerance induction therapy: can alter the efficacy of Kovaltry.

Moderate Interactions (Monitor Closely)

• Antifibrinolytic agents (e.g., tranexamic acid): may enhance clot stability, requiring careful monitoring.
• Live vaccines: immune response may be affected; schedule vaccinations appropriately.
• Immunosuppressive drugs: may modify inhibitor formation risk.